Intestinal Anti-transglutaminase 2 Immunoglobulin A Deposits in Children at Risk for Coeliac Disease (CD): Data from the PreventCD Study

Overview

Journal Clin Exp Immunol

Publisher Oxford University Press

Specialty Allergy & Immunology

Date 2017 Nov 9

PMID 29114847

Citations 12

Authors

M Borrelli

M Maglio

I R Korponay-Szabo

V Vass

M L Mearin

C Meijer

H Niv-Drori

C Ribes-Koninckx

M Roca

R Shamir

R Troncone

R Auricchio

Affiliations

Soon will be listed here.

Abstract

In coeliac disease (CD), anti-tissue transglutaminase 2 immunoglobulin (Ig)A antibodies (anti-TG2) are produced and deposited in the intestine. PreventCD (www.preventcd.com) is a European multi-centre study, which investigates the influence of infant nutrition and that of genetic, immunological and other environmental factors on the risk of developing CD. The aim of the current study was to evaluate the appearance of intestinal anti-TG2 deposits in very early intestinal biopsies from at-risk infants and their predictive value for villous atrophy. Sixty-five small bowel biopsies, performed in 62 children, were investigated for the presence of intestinal anti-TG2 extracellular IgA deposits by using double immunofluorescence. The biopsies were performed in the presence of elevated serum levels of CD-associated antibodies and/or symptoms suggesting disease. Deposits of anti-TG2 IgA were present in 53 of 53 CD patients and three of three potential CD patients. In potential CD patients, mucosal deposits showed a patchy distribution characterized by some areas completely negative, whereas active CD patients had uniformly present and evident mucosal deposits. Only one of six patients without CD (negative for serum anti-TG2 and with normal mucosa) had intestinal deposits with a patchy distribution and a weak staining. Two of the 53 CD patients received a definitive diagnosis of CD after a second or third biopsy; mucosal deposits of anti-TG2 IgA were evaluated in all samples. Before developing villous atrophy, both patients had anti-TG2 deposits in normal mucosal architecture, antibodies in one patient being absent in serum. We demonstrated that in CD the intestinal deposits of anti-TG2 are a constant presence and appear very early in the natural history of disease.

Citing Articles

Role of Protein Tyrosine Phosphatases in Inflammatory Bowel Disease, Celiac Disease and Diabetes: Focus on the Intestinal Mucosa.

Bellomo C, Furone F, Rotondo R, Ciscognetti I, Carpinelli M, Nicoletti M Cells. 2024; 13(23).

PMID: 39682729 PMC: 11640621. DOI: 10.3390/cells13231981.

Cutaneous Disorders Masking Celiac Disease: Case Report and Mini Review with Proposal for a Practical Clinical Approach.

Ancona S, Bianchin S, Zampatti N, Nosratian V, Bigatti C, Ferro J Nutrients. 2024; 16(1).

PMID: 38201912 PMC: 10780572. DOI: 10.3390/nu16010083.

Celiac Disease in Children: A 2023 Update.

Bolia R, Thapar N Indian J Pediatr. 2023; 91(5):481-489.

PMID: 37289309 DOI: 10.1007/s12098-023-04659-w.

Type 2 Transglutaminase in Coeliac Disease: A Key Player in Pathogenesis, Diagnosis and Therapy.

Paolella G, Sposito S, Romanelli A, Caputo I Int J Mol Sci. 2022; 23(14).

PMID: 35886862 PMC: 9318967. DOI: 10.3390/ijms23147513.

Emerging Biomarkers for Screening and Management of Celiac Disease.

Mir B, Majeed T, Singh A, Rajput M, Kumar A, Chauhan A Biomed Res Int. 2022; 2022:2756242.

PMID: 35669726 PMC: 9167106. DOI: 10.1155/2022/2756242.

References

Auricchio R, Tosco A, Piccolo E, Galatola M, Izzo V, Maglio M . Potential celiac children: 9-year follow-up on a gluten-containing diet. Am J Gastroenterol. 2014; 109(6):913-21. DOI: 10.1038/ajg.2014.77. View

Tosco A, Aitoro R, Auricchio R, Ponticelli D, Miele E, Paparo F . Intestinal anti-tissue transglutaminase antibodies in potential coeliac disease. Clin Exp Immunol. 2012; 171(1):69-75. PMC: 3530097. DOI: 10.1111/j.1365-2249.2012.04673.x. View

Koskinen O, Collin P, Lindfors K, Laurila K, Maki M, Kaukinen K . Usefulness of small-bowel mucosal transglutaminase-2 specific autoantibody deposits in the diagnosis and follow-up of celiac disease. J Clin Gastroenterol. 2009; 44(7):483-8. DOI: 10.1097/MCG.0b013e3181b64557. View

Dieterich W, Ehnis T, Bauer M, Donner P, Volta U, Riecken E . Identification of tissue transglutaminase as the autoantigen of celiac disease. Nat Med. 1997; 3(7):797-801. DOI: 10.1038/nm0797-797. View

Vriezinga S, Auricchio R, Bravi E, Castillejo G, Chmielewska A, Crespo Escobar P . Randomized feeding intervention in infants at high risk for celiac disease. N Engl J Med. 2014; 371(14):1304-15. DOI: 10.1056/NEJMoa1404172. View

. Revised criteria for diagnosis of coeliac disease. Report of Working Group of European Society of Paediatric Gastroenterology and Nutrition. Arch Dis Child. 1990; 65(8):909-11. PMC: 1792502. DOI: 10.1136/adc.65.8.909. View

Oberhuber G, Granditsch G, Vogelsang H . The histopathology of coeliac disease: time for a standardized report scheme for pathologists. Eur J Gastroenterol Hepatol. 1999; 11(10):1185-94. DOI: 10.1097/00042737-199910000-00019. View

Salmi T, Collin P, Korponay-Szabo I, Laurila K, Partanen J, Huhtala H . Endomysial antibody-negative coeliac disease: clinical characteristics and intestinal autoantibody deposits. Gut. 2006; 55(12):1746-53. PMC: 1856451. DOI: 10.1136/gut.2005.071514. View

Giersiepen K, Lelgemann M, Stuhldreher N, Ronfani L, Husby S, Koletzko S . Accuracy of diagnostic antibody tests for coeliac disease in children: summary of an evidence report. J Pediatr Gastroenterol Nutr. 2012; 54(2):229-41. DOI: 10.1097/MPG.0b013e318216f2e5. View

10.

Salmi T, Collin P, Jarvinen O, Haimila K, Partanen J, Laurila K . Immunoglobulin A autoantibodies against transglutaminase 2 in the small intestinal mucosa predict forthcoming coeliac disease. Aliment Pharmacol Ther. 2006; 24(3):541-52. DOI: 10.1111/j.1365-2036.2006.02997.x. View

11.

Tosco A, Maglio M, Paparo F, Rapacciuolo L, Sannino A, Miele E . Immunoglobulin A anti-tissue transglutaminase antibody deposits in the small intestinal mucosa of children with no villous atrophy. J Pediatr Gastroenterol Nutr. 2008; 47(3):293-8. DOI: 10.1097/MPG.0b013e3181677067. View

12.

Marzari R, Sblattero D, Florian F, Tongiorgi E, Not T, Tommasini A . Molecular dissection of the tissue transglutaminase autoantibody response in celiac disease. J Immunol. 2001; 166(6):4170-6. DOI: 10.4049/jimmunol.166.6.4170. View

13.

Korponay-Szabo I, Halttunen T, Szalai Z, Laurila K, Kiraly R, Kovacs J . In vivo targeting of intestinal and extraintestinal transglutaminase 2 by coeliac autoantibodies. Gut. 2004; 53(5):641-8. PMC: 1774023. DOI: 10.1136/gut.2003.024836. View

14.

Tosco A, Salvati V, Auricchio R, Maglio M, Borrelli M, Coruzzo A . Natural history of potential celiac disease in children. Clin Gastroenterol Hepatol. 2010; 9(4):320-5. DOI: 10.1016/j.cgh.2010.09.006. View

15.

Husby S, Koletzko S, Korponay-Szabo I, Mearin M, Phillips A, Shamir R . European Society for Pediatric Gastroenterology, Hepatology, and Nutrition guidelines for the diagnosis of coeliac disease. J Pediatr Gastroenterol Nutr. 2011; 54(1):136-60. DOI: 10.1097/MPG.0b013e31821a23d0. View

16.

Kaukinen K, Peraaho M, Collin P, Partanen J, Woolley N, Kaartinen T . Small-bowel mucosal transglutaminase 2-specific IgA deposits in coeliac disease without villous atrophy: a prospective and randomized clinical study. Scand J Gastroenterol. 2005; 40(5):564-72. DOI: 10.1080/00365520510023422. View

17.

Maglio M, Tosco A, Auricchio R, Paparo F, Colicchio B, Miele E . Intestinal deposits of anti-tissue transglutaminase IgA in childhood celiac disease. Dig Liver Dis. 2011; 43(8):604-8. DOI: 10.1016/j.dld.2011.01.015. View